A Study of CP-COV03 Compared With Placebo in Participants With Dengue (Part 1) and Dengue-like Illness (Part 2)

[Part 1] Incidence and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs)

The incidence and severity of AEs / SAEs will be summarized by treatment group. Clinical laboratory abnormalities, vital sign changes, and electrocardiogram (ECG) findings will be reported as AEs if they are considered clinically significant.

Time frame: From start of study intervention (Day 1) up to end of safety follow-up (Day 29)

[Part 1] Average of dengue viral load on Day 3

The area under the log-transformed DENV RNA viral load (log10 VL) curve from baseline until Day 3 will be determined. The viral load is measured in plasma samples using reverse transcription polymerase chain reaction (RT-PCR).

Time frame: Baseline, Day 1, 2, 3

[Part 2] Time to sustained symptom improvement up to Day 15

Sustained improvement of each targeted symptom is defined as the event occurring on the first 2 consecutive days when each symptom scored as moderate or severe at the time of enrollment is scored as mild or absent, and those scored mild or absent at the time of enrollment are scored as absent.

Time frame: From baseline up to Day 15